Propanc Biopharma, Inc.: Form 10-Q for the period ended Dec 31, 2018
Filed with the SEC on Feb 14, 2019 and accepted by EDGAR at Feb 14, 2019, 16:07 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2018-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Cost of revenue | 3 months2018-10-01 to 2018-12-31 | $6.4k | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months2018-07-01 to 2018-12-31 | $14.5k | us-gaap:CostOfGoodsAndServicesSold |
| Research and development | 3 months2018-10-01 to 2018-12-31 | $94.8k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2018-07-01 to 2018-12-31 | $151.0k | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2018-10-01 to 2018-12-31 | −$757.8k | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2018-07-01 to 2018-12-31 | −$1.2m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2018-10-01 to 2018-12-31 | $495.0k | us-gaap:InterestExpense |
| Interest expense | 6 months2018-07-01 to 2018-12-31 | $1.1m | us-gaap:InterestExpense |
| Income tax | 3 months2018-10-01 to 2018-12-31 | −$117.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2018-07-01 to 2018-12-31 | −$117.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2018-10-01 to 2018-12-31 | −$1.5m | us-gaap:NetIncomeLoss |
| Net income | 6 months2018-07-01 to 2018-12-31 | −$3.6m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2018-10-01 to 2018-12-31 | −$0.08 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 6 months2018-07-01 to 2018-12-31 | −$0.02 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 6 months2018-07-01 to 2018-12-31 | −$1.1m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2018-07-01 to 2018-12-31 | $1.7k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2018-12-31 | $124.5k | us-gaap:Cash |
| Current assets | At period end2018-12-31 | $388.1k | us-gaap:AssetsCurrent |
| Total assets | At period end2018-12-31 | $712.6k | us-gaap:Assets |
| Current liabilities | At period end2018-12-31 | $4.6m | us-gaap:LiabilitiesCurrent |
| Long-term debt | At period end2018-12-31 | $2.8m | us-gaap:LongTermDebt |
| Shareholders' equity | At period end2018-12-31 | −$3.9m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001493152-19-002072. Last ingested by Listed: Oct 29, 2026, 17:01 ET. Listed shows no prices and gives no investment advice.